Skip to main content
Premium Trial:

Request an Annual Quote

Swedish Pharma Firm Selects Certara's Software for Drug Discovery


Certara said this week that Medivir, a Swedish pharmaceutical company that focuses on infectious diseases such as hepatitis C, has selected its D360 software as its global drug discovery platform.

According to Certara, Medivir will use D360 — an integrated solution for querying, analyzing, and visualizing drug discovery data — to deliver chemical structure and biological assay data and analytic tools to its discovery chemists and biologists based in Stockholm and Cambridge, UK.

Peter Lind, Medivir's informatics manager, said in a statement that his firm selected Certara's product because it needed a flexible solution "that would allow our discovery scientists to collaborate more effectively, and make informed decisions using all the available data."

The financial details of the agreement were not disclosed.